Stifel Nicolaus analyst Annabel Samimy downgraded the rating on Clearside Biomedical to a Hold today, setting a price target of $2.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Annabel Samimy’s rating is based on Clearside Biomedical’s current strategic and financial challenges. The company is facing a difficult financing environment and has reached the end of its cash runway without securing new capital. As a result, Clearside is exploring strategic alternatives and has halted all development programs, transitioning employees to consulting roles to preserve cash and maximize the remaining value of its platform.
Despite having a promising SCS Microinjector platform and a Ph.3-ready asset in CLS-AX/TKI for wAMD, Clearside has not been able to secure further financing or partnerships. The company’s efforts to extend its cash life into the next year are uncertain, and while it continues to support its partner programs, the outcome of its strategic initiatives remains unclear. Given these uncertainties, Annabel Samimy has downgraded the stock to a Hold rating with a target price of $2.
In another report released today, JonesTrading also downgraded the stock to a Hold with a $0.84 price target.